Dynamic monitoring of EGFR mutations in circulating tumor DNA for early detection of drug resistance in NSCLC patients on EGFR-TKI therapy
A. Szpechcinski (Warsaw, Poland), M. Bryl (Poznan, Poland), G. Czyzewicz (Cracow, Poland), E. Wojda (Warsaw, Poland), D. Swiniuch (Poznan, Poland), M. Szwiec (Zielona Gora, Poland), S. Rudzinski (Warsaw, Poland), K. Duk (Warsaw, Poland), R. Ramlau (Poznan, Poland), P. Sliwinski (Warsaw, Poland), A. Barinow-Wojewodzki (Poznan, Poland), J. Chorostowska-Wynimko (Warsaw, Poland)
Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer
Session: Diagnostic procedures and biology of lung cancer
Session type: Oral Presentation
Number: 1909
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Szpechcinski (Warsaw, Poland), M. Bryl (Poznan, Poland), G. Czyzewicz (Cracow, Poland), E. Wojda (Warsaw, Poland), D. Swiniuch (Poznan, Poland), M. Szwiec (Zielona Gora, Poland), S. Rudzinski (Warsaw, Poland), K. Duk (Warsaw, Poland), R. Ramlau (Poznan, Poland), P. Sliwinski (Warsaw, Poland), A. Barinow-Wojewodzki (Poznan, Poland), J. Chorostowska-Wynimko (Warsaw, Poland). Dynamic monitoring of EGFR mutations in circulating tumor DNA for early detection of drug resistance in NSCLC patients on EGFR-TKI therapy. 1909
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: